A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422 on ClinicalTrials.gov · last registry update 2026-05-29
An unusually large phase 3: 974 participants, more than double the 424 typical for the stage. Due to report September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Number of Participants Allocated to Each ISA. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 974
- Started
- 2025-04-30
- Primary completion
- 2027-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants Allocated to Each ISA
Conditions studied
Hypertension
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.